Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAMBA-D: HepB mAb19 in Chronic Hepatitis D Infection
NCT07610772Phase 1Recruiting
- Sponsor
- Aarhus University Hospital
- Start
- Apr 2026
- Primary completion
- Apr 2028
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of HepB mAb19 in hepatitis D (HDV) and hepatitis B (HBV), sponsored by Aarhus University Hospital. Primary endpoints: Safety and tolerability at 60 weeks and Pharmacokinetic profile at 60 weeks. Started Apr 2026; status: recruiting.
02
Drugs
HepB mAb19
03
Conditions
hepatitis D (HDV)hepatitis B (HBV)
Beyond the preview
Go deeper on NCT07610772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07610772.